奥马珠单抗治疗柏树花粉过敏所致季节性变应性鼻炎的效果

Efficacy of omalizumab in treatment of Sabina chinensis pollen-induced seasonal allergic rhinitis

目的本研究拟探讨奥马珠单抗治疗柏树花粉过敏所致季节性变应性鼻炎的效果。方法在柏树花粉季结束后招募柏树花粉过敏所致季节性鼻炎患者,根据患者是否在花粉季使用奥马珠单抗治疗将患者分为两组,使用者为单抗组,未使用者为对照组,回顾性比较两组患者在花粉季期间鼻结膜炎症状评分,对症用药评分,以及鼻结膜炎生活质量评分。结果在柏树花粉季期间,单抗组患者(n=25)鼻结膜炎症状评分低于对照组(n=50),2.8±1.1 vs.3.3±1.2,P=0.001;单抗组对症用药评分也低于对照组,2.6±1.0 vs.4.4±1.3,P<0.001;但两组患者鼻结膜炎生活质量评分比较没有显著差异。单抗组患者注射奥马珠单抗的剂量与其高峰期症状评分或用药评分均呈显著负相关(r=-0.466和r=-0.530,P<0.05)。结论奥马珠单抗有助于减轻柏树花粉过敏所致季节性鼻炎患者的鼻结膜炎症状,减少对症药物的用量,但其疗效可能受到注射剂量的影响。

Objective To investigate the efficacy of omalizumab in treatment of Sabina chinensis(cypress)pollen-induced seasonal allergic rhinitis.Methods A retrospective study was designed.Patients with cypress pollen-induced seasonal allergic rhinitis were recruited at the end of cypress pollen season and divided into monoclonal antibody and control group respectively,according to the administration of omalizumab during pollen season.Symptom scores,rescue medication scores,and life quality scores of rhinoconjunctivitis during pollen season were recorded and compared between two groups.Results During cypress pollen season,symptom score of monoclonal antibody group(n=25)was significantly lower than that of control group(n=50)(2.8±1.1 vs.3.3±1.2,P=0.001).Rescue medication score of monoclonal antibody group was also significantly lower than that of control group(2.6±1.0 vs.4.4±1.3,P<0.001).However,there was no significant difference statistically between life quality score of two groups.The administration dose of omalizumab in monoclonal antibody group was negatively correlated with both symptom score(r=-0.466,P=0.019)and medication score(r=-0.530,P=0.006)during peak period of pollen season.Conclusions Omalizumab could of help to alleviate rhinoconjunctivitis symptom of patients with cypress pollen-induced seasonal allergic rhinitis and reduce use of rescue medication,but its efficacy might be affected by dose of administration.